Trial Profile
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs AGTC 401 (Primary)
- Indications Colour vision defects
- Focus Adverse reactions; First in man
- Sponsors Applied Genetic Technologies Corporation; Beacon Therapeutics
- 20 Jul 2022 Planned End Date changed from 1 Sep 2025 to 1 Jul 2026.
- 20 Jul 2022 Planned primary completion date changed from 1 Sep 2021 to 1 Jul 2022.
- 20 Jul 2022 Status changed from recruiting to active, no longer recruiting.